Newtyn Management’s Sage Therapeutics SAGE Stock Holding History

Newtyn Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-700,000	Closed	-$6.38M	–	39
2025 Q2	$6.38M	Buy	+700,000	New	+$5.15M	0.97%	24

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Newtyn Management's SAGE Position: Q3 2025 in Review

Newtyn Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 700,000 shares — an estimated $6.38M sold.

Newtyn Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $6.38M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Newtyn Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Newtyn Management sold 700,000 Sage Therapeutics shares in Q3 2025, an estimated $6.38M.
Newtyn Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
Newtyn Management's Sage Therapeutics position peaked at $6.38M in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Newtyn Management's 13F filing for Q3 2025, filed 14 Nov 2025.